Volume 2, Issue 1 (2021)

1. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderateto-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399. 

2. https://www.has-sante.fr/jcms/c_2585408/fr/otezlaapremilast-immunosuppresseur-inhibiteur-de-pde4 

3. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49. 

4. https://www.who.int/fr/news-room/fact-sheets/detail/ diarrhoeal-disease 

5. https://ctep.cancer.gov/protocoldevelopment/electronic_ applications/docs/ctcae_v5_quick_reference_5x7.pdf 

6. Lambert JA, Raju SV, Tang LP, McNicholas CM, Li Y, Courville CA, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2014;50(3):549-558. 

7. Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45(11):1345-1348. 

8. https://www.ema.europa.eu/en 9. Tello ED, Suárez JA, Catalán EB, Maldonado CB, Manso MCH, Morales AJ, et al. Manejo de los efectos adversos de apremilast desde un abordaje multidisciplinarMultidisciplinary Management of the Adverse Effects of Apremilast. Actas Dermosifiliogr. 2021;112(2):134-141.